Computational toxicology in drug development.

Computational tools for predicting toxicity have been envisaged for their potential to considerably impact the attrition rate of compounds in drug discovery and development. In silico techniques like knowledge-based expert systems (quantitative) structure activity relationship tools and modeling approaches may therefore help to significantly reduce drug development costs by succeeding in predicting adverse drug reactions in preclinical studies. It has been shown that commercial as well as proprietary systems can be successfully applied in the pharmaceutical industry. As the prediction has been exhaustively optimized for early safety-relevant endpoints like genotoxicity, future activities will now be directed to prevent the occurrence of undesired toxicity in patients by making these tools more relevant to human disease.

[1]  Hua-rong Lu,et al.  Calmodulin Antagonist W‐7 Prevents Sparfloxacin‐Induced Early Afterdepolarizations (EADs) in Isolated Rabbit Purkinje Fibers: Importance of Beat‐to‐Beat Instability of the Repolarization , 2006, Journal of cardiovascular electrophysiology.

[2]  A. Debnath,et al.  Structure-activity relationship of mutagenic aromatic and heteroaromatic nitro compounds. Correlation with molecular orbital energies and hydrophobicity. , 1991, Journal of medicinal chemistry.

[3]  G. Klopman.  MULTICASE 1. A Hierarchical Computer Automated Structure Evaluation Program , 1992 .

[4]  Takashi Okada,et al.  Characteristic Substructures and Properties in Chemical Carcinogens Studied by the Cascade Model , 2003, Bioinform..

[5]  S. Sudarsanam,et al.  Future of Computational Toxicology: Broad Application into Human Disease and Therapeutics , 2006 .

[6]  Terry S Peters,et al.  Do Preclinical Testing Strategies Help Predict Human Hepatotoxic Potentials? , 2005, Toxicologic pathology.

[7]  D. Lewis,et al.  COMPACT: a structural approach to the modelling of cytochromes P450 and their interactions with xenobiotics , 2001 .

[8]  M. Hashimoto,et al.  [Draft ICH guideline S7B: guideline on safety pharmacology studies for assessing the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals]. , 2003, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

[9]  D. Lewis,et al.  Validation of a novel molecular orbital approach (COMPACT) for the prospective safety evaluation of chemicals, by comparison with rodent carcinogenicity and Salmonella mutagenicity data evaluated by the U.S. NCI/NTP. , 1993, Mutation research.

[10]  Vladimir Poroikov,et al.  Pass: Prediction of Biological Activity Spectra for Substances , 2005 .

[11]  T. Kelly,et al.  Regulation of chromosome replication. , 2000, Annual review of biochemistry.

[12]  Lei Zhang,et al.  Kinase inhibitor recognition by use of a multivariable QSAR model. , 2006, Journal of molecular graphics & modelling.

[13]  R D Benz,et al.  Use of toxicological information in drug design. , 2000, Journal of molecular graphics & modelling.

[14]  Hao G. Nguyen,et al.  Mechanism of Aurora-B Degradation and Its Dependency on Intact KEN and A-Boxes: Identification of an Aneuploidy-Promoting Property , 2005, Molecular and Cellular Biology.

[15]  A. Camm,et al.  Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.

[16]  Y. Kasuya,et al.  Pathway -terminal Kinase 2 Partly via Blockade of C-jun Nh Α Activated Receptor- − Proliferator Induced Cardiac Hypertrophy Is Inhibited by Activation of Peroxisome − Endothelin-1 Endothelin-1–induced Cardiac Hypertrophy Is Inhibited by Activation of Peroxisome Proliferator–activated Receptor-␣ Part , 2004 .

[17]  G. Zlokarnik,et al.  In silico prediction of drug safety: despite progress there is abundant room for improvement. , 2004, Drug discovery today. Technologies.

[18]  Wolfgang Muster,et al.  Strategies for Using Computational Toxicology Methods in Pharmaceutical R&D , 2006 .

[19]  Sean Ekins.  Computational toxicology : risk assessment for pharmaceutical and environmental chemicals , 2007 .

[20]  Emilio Benfenati,et al.  The Expanding Role of Predictive Toxicology: An Update on the (Q)SAR Models for Mutagens and Carcinogens , 2007, Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews.

[21]  Yuejin Wu,et al.  Death, Cardiac Dysfunction, and Arrhythmias Are Increased by Calmodulin Kinase II in Calcineurin Cardiomyopathy , 2006, Circulation.

[22]  L. Siu,et al.  Molecularly targeted oncology therapeutics and prolongation of the QT interval. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Paul B Bennett,et al.  Trends in ion channel drug discovery: advances in screening technologies. , 2003, Trends in biotechnology.

[24]  Gerd Folkers,et al.  Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies , 2006 .

[25]  T. Hartung,et al.  Thiazolidinedione bioactivation: a comparison of the bioactivation potentials of troglitazone, rosiglitazone, and pioglitazone using stable isotope-labeled analogues and liquid chromatography tandem mass spectrometry. , 2006, Chemical research in toxicology.

[26]  J. Contrera,et al.  Predicting the carcinogenic potential of pharmaceuticals in rodents using molecular structural similarity and E-state indices. , 2003, Regulatory toxicology and pharmacology : RTP.

[27]  Borje Darpo,et al.  Clinical Evaluation of QT/QTc Prolongation and Proarrhythmic Potential for Nonantiarrhythmic Drugs: The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 Guideline , 2006, Journal of clinical pharmacology.

[28]  Zhengyin Yan,et al.  Screening for reactive intermediates and toxicity assessment in drug discovery. , 2006, Current opinion in drug discovery & development.

[29]  T. Nikolskaya,et al.  Algorithms for network analysis in systems-ADME/Tox using the MetaCore and MetaDrug platforms , 2006, Xenobiotica; the fate of foreign compounds in biological systems.

[30]  Glenn J. Myatt,et al.  LeadScope: Software for Exploring Large Sets of Screening Data , 2000, J. Chem. Inf. Comput. Sci..

[31]  Paul Taylor,et al.  Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance , 2006, Nature chemical biology.

[32]  A. Chakravarty,et al.  MLN8054, a Small-Molecule Inhibitor of Aurora A, Causes Spindle Pole and Chromosome Congression Defects Leading to Aneuploidy , 2007, Molecular and Cellular Biology.

[33]  D. Roden.  Drug-induced prolongation of the QT interval. , 2004, The New England journal of medicine.

[34]  Philip Judson.  Using Computer Reasoning about Qualitative and Quantitative Information to Predict Metabolism and Toxicity , 2007 .

[35]  R Daniel Benz,et al.  Toxicological and clinical computational analysis and the US FDA/CDER , 2007, Expert opinion on drug metabolism & toxicology.

[36]  Su-Ying Wu,et al.  Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop. , 2003, Structure.

[37]  L. Meijer,et al.  Chemical inhibitors of cyclin-dependent kinases. , 1996, Trends in cell biology.

[38]  Rainer Franke,et al.  General Introduction to QSAR , 2003 .

[39]  Nigel Greene,et al.  Computer systems for the prediction of toxicity: an update. , 2002, Advanced drug delivery reviews.

[40]  J. Bauer,et al.  Intracellular distribution of peroxynitrite during doxorubicin cardiomyopathy: evidence for selective impairment of myofibrillar creatine kinase , 2002, British journal of pharmacology.

[41]  I Gerner,et al.  Development of a Decision Support System for the Introduction of Alternative Methods into Local Irritancy/Corrosivity Testing Strategies. Development of a Relational Database , 2000, Alternatives to laboratory animals : ATLA.

[42]  Ferenc Darvas,et al.  HazardExpert: An Expert System for Predicting Chemical Toxicity , 1992 .

[43]  N. Ahmad,et al.  Regulation of mitosis via mitotic kinases: new opportunities for cancer management , 2007, Molecular Cancer Therapeutics.

[44]  D. Thompson,et al.  Role of Metabolism in Drug-Induced Idiosyncratic Hepatotoxicity , 2005, Critical reviews in toxicology.

[45]  Markus A Lill,et al.  The challenge of predicting drug toxicity in silico. , 2006, Basic & clinical pharmacology & toxicology.

[46]  Steven L. Dixon,et al.  In silico models for the prediction of dose-dependent human hepatotoxicity , 2003, J. Comput. Aided Mol. Des..

[47]  Christoph Helma,et al.  Lazy structure-activity relationships (lazar) for the prediction of rodent carcinogenicity and Salmonella mutagenicity , 2006, Molecular Diversity.

[48]  A. Leo,et al.  The expanding role of quantitative structure-activity relationships (QSAR) in toxicology. , 1995, Toxicology letters.

[49]  J. Ruskin,et al.  Drug‐Induced Torsades de Pointes and Implications for Drug Development , 2004, Journal of cardiovascular electrophysiology.

[50]  T. Wallimann,et al.  Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply. , 2005, American journal of physiology. Heart and circulatory physiology.

[51]  Yin-tak Woo,et al.  OncoLogic: A Mechanism-Based Expert System for Predicting the Carcinogenic Potential of Chemicals , 2005 .

[52]  Yu Zong Chen,et al.  Current QSAR Techniques for Toxicology , 2006 .

[53]  John D. Walker,et al.  Quantitative structure–activity relationships (QSARs) in toxicology: a historical perspective , 2003 .

[54]  R. Hajjar,et al.  Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. , 2004, Journal of the American College of Cardiology.

[55]  P. Singal,et al.  Oxidative Stress and Apoptosis in Heart Dysfunction , 2002, Herz.

[56]  I Gerner,et al.  Development of a Decision Support System for the Introduction of Alternative Methods into Local Irritancy/Corrosivity Testing Strategies. Creation of Fundamental Rules for a Decision Support System , 2000, Alternatives to laboratory animals : ATLA.

[57]  L. Meijer,et al.  Anti-mitotic properties of indirubin-3′-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest , 2001, Oncogene.

[58]  J. Breed,et al.  SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[59]  John Sharkey,et al.  Acquired QT interval prolongation and HERG: implications for drug discovery and development. , 2004, European journal of pharmacology.

[60]  F. Ballet,et al.  Hepatotoxicity in drug development: detection, significance and solutions. , 1997, Journal of hepatology.

[61]  E. Greselin.  An inhibitor of cholesterol biosynthesis and the alveolar macrophages. , 1966, Canadian journal of comparative medicine and veterinary science.

[62]  R. A. Etten,et al.  Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition , 2007, Nature Reviews Cancer.

[63]  J. Peters,et al.  The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore–microtubule attachment and in maintaining the spindle assembly checkpoint , 2003, The Journal of cell biology.

[64]  Remigijus Didziapetris,et al.  In silico technology for identification of potentially toxic compounds in drug discovery , 2006 .

[65]  Romualdo Benigni,et al.  Quantitative Structure-Activity Relationship (QSAR) Models of Mutagens and Carcinogens , 2003 .

[66]  J. Contrera,et al.  A new highly specific method for predicting the carcinogenic potential of pharmaceuticals in rodents using enhanced MCASE QSAR-ES software. , 1998, Regulatory toxicology and pharmacology : RTP.

[67]  J. Peters,et al.  The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights into Mitotic Roles of Polo-like Kinase 1 , 2007, Current Biology.

[68]  Naomi L Kruhlak,et al.  Comparison of MC4PC and MDL-QSAR rodent carcinogenicity predictions and the enhancement of predictive performance by combining QSAR models. , 2007, Regulatory toxicology and pharmacology : RTP.